Vir/GSK Move Lead Coronavirus Antibody Into Phase III

Safety In 20 Phase II Patients Enabled Testing In 1,300 People

 
• By Mandy Jackson
  
Immunological system, antibodies attacking the virus covid-19. 3D illustration, concept of the body's defense system. Y-shaped antibody attacking the coronavirus.
VIR-7831 is engineered to neutralize SARS-CoV-2, with limited treatment resistance, enhanced lung bioavailability and an extended half-life • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

More from Scrip